🔗 Share this article

Elected officials have expressed alarm that the United Kingdom's negotiated accords with Donald Trump are "lacking a solid foundation." This stems from revelations that a recently announced deal on pharmaceutical tariffs, which commits to zero tariffs in exchange for the NHS paying more, lacks any detailed agreement beyond limited headline terms published in government press releases.

An Agreement in Principle Only

The US-UK pharmaceuticals agreement, promoted as a "significant" achievement, is still an "broad understanding" without a signed legal text. It has been highlighted that the press releases from the UK and US governments describe the deal in divergent terms. The British version celebrates securing "zero per cent tariffs" as a singular success, while the American announcement highlights the commitment for the NHS to pay higher prices for new medications.

"The danger exists that the UK government has agreed to terms to increase medicine costs in return for only a assurance from President Trump," said David Henig, a trade policy analyst. "We know he has a tendency for not following through on agreements."

Broader Instability and a Paused Tech Deal

Worries have been amplified by Washington's move to pause the high-value digital accord, which was previously heralded as "a generational step-change" in the bilateral relationship. The US claimed a failure to advance from the UK on lowering trade barriers as the reason for the pause.

Additionally, concessions secured for British farmers as part of an initial accord have still not been formally ratified by the US, despite a imminent January deadline. "We have been informed that that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Behind the scenes, ministers have voiced worries that the government's US-UK accords are flimsy and unreliable. One minister reportedly said the series of agreements as "built on sand," while another characterized the situation as the "new normal" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, a senior MP on the health committee, remarked: "What is even more astonishing than the administration's tactics is the UK government's credulous faith that his administration is a trustworthy negotiator. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Ministry sources have downplayed the possibility of the US withdrawing from the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been lobbying for the agreement, wanting clarity on imports and pricing, making it of tangible value than the paused tech deal.

Officials admit that volatility is a feature of dealing with the Trump administration. However, they contend that the UK has achieved real benefits for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is lower than the rate for the rest of the world, is a concrete advantage," one official said.

Nevertheless, delays have surfaced in carrying out the May tariff agreement. Promised quotas on beef exports have yet to be finalized, and the pledge to "reduce steel tariffs to zero" has not been fulfilled, with tariffs remaining at 25%.

Looking ahead, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "constructive" meetings between UK and US officials in Washington.